NCT02454062 - A Trial of TAS-114 in Combination With S-1 | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 27, 2016

Study Completion Date

September 30, 2017

Conditions

Advanced Solid Tumors

Interventions

DRUG

TAS-114

TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.

DRUG

S-1

S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)

Trial Locations (5)

Erasme University Hospital-ULB, Brussels

IOSI Istituto Oncologico della Svizzera Italiana, Bellinzona

IRCCS San Marino IST, Genoa

Universita Vita-Salute San Raffaele, Milan

Institut Gustave Roussy, Villejuif

All Listed Sponsors

lead

Taiho Oncology, Inc.

INDUSTRY